Zhi Tong Cai Jing·2025-09-01 02:00Core Viewpoint - Junshi Biosciences (01877) reported a significant increase in revenue and a reduction in net loss for the first half of 2025, indicating a positive trend in its commercial drug sales and operational efficiency [1] Financial Performance - The company achieved a revenue of approximately 1.168 billion yuan, representing a year-on-year growth of 48.64% [1] - The net loss attributable to shareholders was about 413 million yuan, which is a reduction of approximately 36% compared to the previous year [1] - Basic loss per share was reported at 0.42 yuan [1] Revenue Growth Drivers - Revenue growth was primarily driven by the sales of commercialized drugs, with sales in the domestic market reaching 954 million yuan, an increase of about 42% year-on-year [1] - The company is focusing on enhancing quality and efficiency while returning value, concentrating on competitive and innovative R&D projects [1] Market Expansion and Future Outlook - Junshi Biosciences' drug, Tuoyi, has been approved for 12 indications in China and has received approvals in 40 countries and regions including Hong Kong, the US, EU, India, the UK, Jordan, Australia, Singapore, UAE, and Kuwait [1] - The company is expected to see accelerated global sales of Tuoyi as new indications for first-line liver cancer and melanoma are anticipated to be approved in the first half of 2025, along with further approvals and integration into health insurance systems [1]